U.S. Department of Health and Human Services

Kidney Diseases Section

Jeffrey B. Kopp, M.D., Chief


A selection of recent and significant publications can be viewed below.

Kopp JB. Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder.Curr. Opin. Nephrol. Hypertens. 2013 Mar 10 (2013 Mar 10) . [Full Text/Abstract]
Chandra P, Kopp JB. Viruses and collapsing glomerulopathy: a brief critical review.Clin Kidney J. 2013 Feb; 6 (6; 2013 Feb; 1) :1-5. [Full Text/Abstract]
Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB, SK Investigators. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.Kidney Int. 2013 Jan; 83 (83; 1; 2013 Jan) :114-20. [Full Text/Abstract]
Balow JE. Glomerular disease: perspectives on maintenance therapy in lupus nephritis.Nat Rev Nephrol. 2012 Feb 7; 8 (8; 2012 Feb 7; 3) :136-8. [Full Text/Abstract]
Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.J. Am. Soc. Nephrol. 2011 Nov; 22 (2011 Nov; 22; 11) :2129-37. [Full Text/Abstract]
Boumpas DT, Bertsias GK, Balow JE. A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?Ann. Rheum. Dis. 2010 Dec; 69 (69; 2010 Dec; 12) :2059-61. [Full Text/Abstract]
Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.Arthritis Rheum. 2010 Feb; 62 (2; 2010 Feb; 62) :542-52. [Full Text/Abstract]
Marasà M, Kopp JB. Monoclonal antibodies for podocytopathies: rationale and clinical responses.Nat Rev Nephrol. 2009 Jun; 5 (6; 2009 Jun; 5) :337-48. [Full Text/Abstract]
Austin HA 3rd, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.J. Am. Soc. Nephrol. 2009 Apr; 20 (2009 Apr; 20; 4) :901-11. [Full Text/Abstract]
Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.Nat. Genet. 2008 Oct; 40 (40; 2008 Oct; 10) :1175-84. [Full Text/Abstract]
Zhou H, Cheruvanky A, Hu X, Matsumoto T, Hiramatsu N, Cho ME, Berger A, Leelahavanichkul A, Doi K, Chawla LS, Illei GG, Kopp JB, Balow JE, Austin HA 3rd, Yuen PS, Star RA. Urinary exosomal transcription factors, a new class of biomarkers for renal disease.Kidney Int. 2008 Sep; 74 (74; 5; 2008 Sep) :613-21. [Full Text/Abstract]
Petri M, Kasitanon N, Lee SS, Link K, Magder L, Bae SC, Hanly JG, Isenberg DA, Nived O, Sturfelt G, van Vollenhoven R, Wallace DJ, Alarcón GS, Adu D, Avila-Casado C, Bernatsky SR, Bruce IN, Clarke AE, Contreras G, Fine DM, Gladman DD, Gordon C, Kalunian KC, Madaio MP, Rovin BH, Sanchez-Guerrero J, Steinsson K, Aranow C, Balow JE, Buyon JP, Ginzler EM, Khamashta MA, Urowitz MB, Dooley MA, Merrill JT, Ramsey-Goldman R, Font J, Tumlin J, Stoll T, Zoma A, Systemic Lupus International Collaborating Clinics. Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index.Arthritis Rheum. 2008 Jun; 58 (6; 2008 Jun; 58) :1784-8. [Full Text/Abstract]
Shrivastav S, Kino T, Cunningham T, Ichijo T, Schubert U, Heinklein P, Chrousos GP, Kopp JB. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy.Mol. Endocrinol. 2008 Feb; 22 (2; 22; 2008 Feb) :234-47. [Full Text/Abstract]
Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis.Clin J Am Soc Nephrol. 2007 Sep; 2 (2; 5; 2007 Sep) :906-13. [Full Text/Abstract]
Musso C, Javor E, Cochran E, Balow JE, Gorden P. Spectrum of renal diseases associated with extreme forms of insulin resistance.Clin J Am Soc Nephrol. 2006 Jul; 1 (4; 1; 2006 Jul) :616-22. [Full Text/Abstract]
Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.Arthritis Rheum. 2004 Jul; 50 (2004 Jul; 7; 50) :2202-10. [Full Text/Abstract]
Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA, Turman MA, Blackett PR, Savage DB, O'Rahilly S, Balow JE, Gorden P. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy.J. Clin. Endocrinol. Metab. 2004 Jul; 89 (2004 Jul; 7; 89) :3199-207. [Full Text/Abstract]
Balow JE, Austin HA 3rd. Maintenance therapy for lupus nephritis--something old, something new.N. Engl. J. Med. 2004 Mar 4; 350 (10; 2004 Mar 4; 350) :1044-6. [Full Text/Abstract]
Balow JE, Austin HA 3rd. Treatment of proliferative lupus nephritis.Am. J. Kidney Dis. 2004 Feb; 43 (2004 Feb; 43; 2) :383-5. [Full Text/Abstract]
Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited.J. Am. Soc. Nephrol. 2004 Feb; 15 (2004 Feb; 2; 15) :241-50. [Full Text/Abstract]
Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A, BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.Arthritis Rheum. 2003 Mar; 48 (48; 2003 Mar; 3) :719-27. [Full Text/Abstract]